Fig. 1

Combination chemotherapy using oxaliplatin and saracatinib induced antagonistic effects on HCC cells. (a) The efficacy of combinations between oxaliplatin and anti-cancer molecular targeting drugs was screened, and the combined chemotherapy with oxaliplatin and saracatinib induced significantly antagonistic effects. (b) Cell viability assays of MHCC97L and Hep3B cells treated with oxaliplatin or saracatinib individually or in combination. (c) Colony formation assays were performed on HCC cells following treatment with either oxaliplatin or saracatinib individually or with both drugs combined. Data are shown as cell colony diameters. (d) The cell cycle distributions were analyzed, and the proportions of cells in S phase were determined for HCC cell lines treated with oxaliplatin or saracatinib individually or in combination. (e) The tumor weight of the subcutaneous xenografts were larger in the combination treatment group than treatment with the single drugs